Hepatocellular Carcinoma (HCC) is the most common type of liver cancer, accounting for around 85% of cases. It is a major health problem particularly in areas endemic with hepatitis B viral infection (HBV). It is the second most common leading cause of death due to cancer worldwide.
Epidemiology[edit | edit source]
Geographic Distribution[edit | edit source]
The rates of HCC are highest at Subsaharan Africa and Far East Asia.
Pathogenesis[edit | edit source]
SOCS-1 can be considered a tumour suppressor gene that is epigenetically silenced through methylation of its promotor region. A recent meta-analysis showed the SOCS-1 promotor was found to be methylated in HCC cases around 3 times more frequently than in surrounding normal tissue or in benign tumours.
Treatment[edit | edit source]
Evaluation of response to sorafenib[edit | edit source]
A study that was done in Japan suggested the use of contrast-based ultrasound to assess the arrival time of the contrast to the liver, and used those measurements as an indicator for response to sorafenib.